Checking a questionnaire on mood and thinking changes in Parkinson's disease
Checks whether a questionnaire on mood and thinking changes gives steady results in Parkinson's.
Plain-language title generated from the registry record
Registry title: Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale in Parkinson's Disease
Key facts
- Where
- Grenoble, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 75 years old?
Source: NCT06701955, who can take part
Where in France
- CHUGAGrenoble, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Grenoble
- Trial code
- NCT06701955
- Record updated
- 30 September 2026
- Original description
This study focuses on neuropsychiatric fluctuations (NPF) in Parkinson's disease. Due to the lack of specific assessment tools, we developed the Neuropsychological Fluctuations Scale (NFS), a 20-item questionnaire. Recent studies have confirmed its reliability, sensitivity, and validity. To finalize its validation, assessing its test-retest reliability is an essential next step.Read full original descriptionShow less
Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale (EFN)
This study focuses on neuropsychiatric fluctuations (NPF) in Parkinson's disease. Due to the lack of specific assessment tools, we developed the Neuropsychological Fluctuations Scale (NFS), a 20-item questionnaire. Recent studies have confirmed its reliability, sensitivity, and validity. To finalize its validation, assessing its test-retest reliability is an essential next step.
Inclusion: Age > 30 and ≤ 75 years; Idiopathic Parkinson's disease (according to the criteria of the Movement Disorders Society); Presence of motor fluctuations described by the patient, their relatives, or identified by the clinician; Stability of antiparkinsonian treatment for at least one month; Mastery of the French language; Able to give consent; Affiliated to the social security system.
Exclusion: Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, parturients, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social establishment for purposes other than research, minors, persons subject to a legal protection measure or unable to express their consent)); Parkinsonian syndrome other than idiopathic Parkinson's disease; Dementia (MoCa < 23); No antiparkinsonian treatment or treatment modified for less than one month; Subject in a period of exclusion from another interventional study.